Government-Owned Inventions; Availability for Licensing, 42351-42352 [05-14498]

Download as PDF Federal Register / Vol. 70, No. 140 / Friday, July 22, 2005 / Notices database to track a wide range of data on biomarkers. Generic data elements selected by the NCI will be incorporated into a database and a set of elements will be chosen to tailor for specific markers for suitability and utilization. The database may be further developed and improved by creation of a web accessible interface providing guidance on how to access a marker of choice according to relevant set of data elements from the foundation; e.g., data elements that best define the marker for specific clinical utilization. Addition and identification of suitable markers within the database and tailoring of data elements could be accomplished by recommendation of a review panel of experts for suitability and/or utilization of selected markers. Marker data will be updated by individual investigators or by a database administrator as additional pertinent information becomes available in the literature on specific marker. A fully enabled database would allow professionals within industry, research and clinical centers to easily access, retrieve and study the state of technology of a specific biomarker at a point of need. Standardization and proper evaluation and packaging of relevant integrated data on cancer biomarkers into a central database should eventually account for characteristics of an individual’s state of health that will not only lead to improved detection of cancer, but also to better prevention and treatment of cancer. Access to archived data will direct industry to better assess the need for development of technologies dependent upon knowledge of the markers and may enhance communication among professionals by enabling them to correspond using a common vocabulary of standardized data elements for biomarkers by referring to the data elements that is the foundation of the database. In order to facilitate the rapid adaptation of the biomarker database, the NCI inventors would be interested in collaborating with qualified commercial entities to develop the technology (software) under terms of a Cooperative Research and Development Agreement (CRADA). Use of 8–C1–cAMP as Anticancer Drug Yoon S. Cho-Chung (NCI) U.S. Patent No. 5,792,752 issued 11 Aug 1998 (HHS Reference No. E–132– 1988/0–US–05) U.S. Patent No. 5,902,794 issued 11 May 1999 (HHS Reference No. E–132– 1988/0–US–06) VerDate jul<14>2003 19:28 Jul 21, 2005 Jkt 205001 Licensing Contact: Michelle A. Booden; (301) 451–7337; boodenm@mail.nih.gov. Site-selective cAMP analogues that preferentially bind and activate PKA–I or PKA–II exhibit specificity not mimicked by parental cAMP. These analogues demonstrate a synergism of binding in appropriate combinations. 8– Cl–cAMP, which belongs to the ISD (isozyme site discriminator) class of site-selective cAMP analogues, activates and down-regulates PKA–I, but not PKA–II, by binding to both site A and B of RI and to site B of RII. 8–Cl–cAMP inhibits growth, in vitro and in vivo, in a broad spectrum of human carcinoma, fibrosarcoma, and leukemia cell lines without causing cytotoxicity. The growth-inhibitory effect of 8–Cl–cAMP correlates with the down-regulation of RI, the up-regulation of RII, and the suppression of c-myc and c-ras oncogene expression. 8–Cl–cAMP is a promising cancer chemotherapeutic agent that in preclinical studies can reverse the transformed phenotype of, and induce apoptotic cell death in, human cancer cells. Results of a Phase I clinical trial suggest that effective plasma levels (determined in preclinical studies) of 8– Cl–cAMP can be maintained below the maximum tolerated dose. More recently, the NCI has initiated and supported ongoing Phase I clinical trials of 8–Cl– cAMP for the treatment of colon cancer and multiple myeloma. The present invention provides compositions and methods for use of cAMP analogs, including 8–Cl–cAMP, as a therapeutic intervention for multiple human diseases. This technology is available for licensing on an exclusive or a nonexclusive basis. In addition to licensing, the technology is available for further development through collaborative research opportunities with the inventors. Dated: July 15, 2005. Steven M. Ferguson, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. 05–14497 Filed 7–21–05; 8:45 am] BILLING CODE 4140–01–P PO 00000 Frm 00053 Fmt 4703 Sfmt 4703 42351 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing National Institutes of Health, Public Health Service, HHS. ACTION: Notice. AGENCY: SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: (301) 496–7057; fax: (301) 402–0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications. Adult Human Dental Pulp Stem Cells in vitro and in vivo Dr. Songtao Shi et al. (NIDCR) U.S. Patent Application No. 10/333,522 filed 17 Jan 2003 (HHS Reference No. E–233–2000/0–US–03), claiming priority to 21 Jul 2000. Licensing Contact: Marlene Shinn-Astor; (301) 435–4426; shinnm@mail.nih.gov. Many individuals with ongoing and severe dental problems are faced with the prospect of permanent tooth loss. Examples include dentinal degradation due to caries or periodontal disease; (accidental) injury to the mouth; and surgical removal of teeth due to tumors associated with the jaw. Clearly, a technology that offers a possible alternative to artificial dentures by designing and transplanting a set of living teeth fashioned from the patient’s own pulp cells would greatly improve the individual’s quality of life. The NIH announces a new technology wherein dental pulp stem cells from an individual’s own postnatal dental pulp tissue (one or two wisdom teeth) can potentially be used to engineer healthy living teeth. This technology is based upon the discovery of a subpopulation of cells within normal human dental E:\FR\FM\22JYN1.SGM 22JYN1 42352 Federal Register / Vol. 70, No. 140 / Friday, July 22, 2005 / Notices ligament (PDL) and the adjacent bone and cementum. The effects of Periodontal Disease range from simple gum inflammation to, in extreme cases, tooth loss. The NIH announces a new technology wherein stem cells from the PDL have been isolated from adult human PDL. Postnatal Stem Cells and Uses Thereof These cells are capable of forming Drs. Songtao Shi and Pamela Robey cementum and PDL in (NIDCR) immunocompromised mice. In cell PCT Application No. PCT/US03/12276 culture, PDL stem cells differentiate into filed 19 Apr 2003 (HHS Reference No. collagen fiber forming cells (fibroblasts), E–018–2003/0–PCT–01), which cementoblasts, and adipocytes. It is published as WO 2004/094588 A2 on anticipated that these PDL stem cells 04 Nov 2004. will be useful for periodontal tissue Licensing Contact: Marlene Shinn-Astor; regeneration to treat periodontal (301) 435–4426; disease. shinnm@mail.nih.gov. Dated: July 15, 2005. Many individuals with ongoing and Steven M. Ferguson, severe dental problems are faced with Director, Division of Technology Development the prospect of permanent tooth loss. and Transfer, Office of Technology Transfer, Examples of such dental problems National Institutes of Health. include: Dentinal degradation due to [FR Doc. 05–14498 Filed 7–21–05; 8:45 am] chronic dental disease (caries or BILLING CODE 4140–01–P periodontal); mouth injury; or through surgical removal, such as with tumors associated with the jaw. For many, a DEPARTMENT OF HEALTH AND technology that offers a possible HUMAN SERVICES alternative to artificial dentures by National Institutes of Health designing and transplanting a set of living teeth fashioned from an Government-Owned Inventions; individual’s own pulp cells would Availability for Licensing greatly improve their quality of life. The NIH announces a new technology AGENCY: National Institutes of Health, wherein human postnatal deciduous Public Health Service, DHHS. dental pulp stem cells commonly ACTION: Notice. known as ‘‘baby teeth’’, are used to create dentin and have been shown to SUMMARY: The inventions listed below differentiate into cells of specialized are owned by an agency of the U.S. function such as neural cells, Government and are available for adipocytes, and odontoblasts. It is licensing in the U.S. in accordance with believed that these cells could be 35 U.S.C. 207 to achieve expeditious manipulated to repair damaged teeth, commercialization of results of induce the regeneration of bone, and federally-funded research and treat neural injury or disease. development. Foreign patent This research is described, in part, in applications are filed on selected Miura et al., ‘‘SHED: Stem cells from inventions to extend market coverage human exfoliated deciduous teeth,’’ for companies and may also be available Proc. Natl. Acad. Sci. USA, vol. 100 (no. for licensing. 10; May 13, 2003) pp. 5807–5812. ADDRESSES: Licensing information and copies of the U.S. patent applications Multipotent Postnatal Stem Cells From Human Periodontal Ligament and Uses listed below may be obtained by writing to the indicated licensing contact at the Thereof Office of Technology Transfer, National Dr. Songtao Shi et al. (NIDCR) Institutes of Health, 6011 Executive PCT Application No. PCT/US04/39248 Boulevard, Suite 325, Rockville, filed 22 Nov 2004 (HHS Reference No. Maryland 20852–3804; telephone: (301) E–033–2004/0–PCT–02), claiming 496–7057; fax: (301) 402–0220. A signed priority to 20 Nov 2003. Confidential Disclosure Agreement will Licensing Contact: Marlene Shinnbe required to receive copies of the Astor; (301) 435–4426; patent applications. shinnm@mail.nih.gov. Cloning of a Genomic DNA Fragment It is estimated that over 40 percent of Containing the Guinea Pig CXCR1 the adult population in the United Gene, a Specific Receptor for Guinea States has periodontal disease in one Pig Interleukin-8 form or another. Periodontal Disease is a chronic infection of the periodontal Teizo Yoshimura (NCI) pulp tissue that has the ability to grow and proliferate in vitro. These (dental pulp) stem cells can be induced under defined culture conditions to form calcified nodules in vitro and have been shown to differentiate into a dentin/ pulp like structure in vivo. VerDate jul<14>2003 19:28 Jul 21, 2005 Jkt 205001 PO 00000 Frm 00054 Fmt 4703 Sfmt 4703 HHS Reference No. E–242–2005/0— Research Tool Licensing Contact: Jesse S. Kindra; (301) 435–5559; kindraj@mail.nih.gov. The present invention relates to cloning of a genomic DNA fragment containing the guinea pig CXCR1 gene, a specific receptor for guinea pig interleukin-8 (IL–8). More specifically, the IL–8–CXCR1 axis is a major chemokine-chemokine receptor system that regulates the recruitment of neutrophils into sites of inflammation. In this invention, the inventors cloned a genomic DNA clone containing the gene for guinea pig IL– 8 receptor CXCR1. Mice and rats are the most commonly used small animals to examine the efficacy of drugs developed for human use. However, neither IL–8 nor CXCR1, a specific receptor for IL– 8, is present in these animals, making it impossible to use them as a model to test the effects or IL–8 or CXCR1 antagonists. Identification of CXCR1, along with IL–8, in the guinea pig may enable evaluation of the in vivo effects of the antagonists. In addition to licensing, the technology is available for further development through collaborative research opportunities with the inventors. Anti-CD30 Antibodies That Bind To Intact CD30 but not to Soluble CD30 Satoshi Nagata and Ira Pastan (NCI) U.S. Provisional Application No. 60/ 681,929 filed 16 May 2005 (HHS Reference No. E–208–2005/0–US–01), Licensing Contact: Jesse S. Kindra; (301) 435–5559; kindraj@mail.nih.gov. Human CD30 is a promising target for cancer immunotherapy since CD30 is highly expressed in Hodgkin’s disease and anaplastic large-cell lymphoma. However, soluble CD30, the extracellular domain of CD30 that is shed from the cells, can reduce the effects of CD30-targeting agents by competitive binding. This invention is the first successful attempt of producing CD30-targeting agents without the disadvantage of the reducing effects caused by soluble CD30. More specifically, two (2) epitopes on membrane-associated CD30 have been identified that are missing on soluble CD30. These epitopes are potentially superior targets for immunotherapy since targeting the epitopes should be free from the competitive effects of soluble CD30. Accordingly, the antibodies described in this invention may be used as targeting reagents for cancer therapy. In addition to licensing, the technology is available for further E:\FR\FM\22JYN1.SGM 22JYN1

Agencies

[Federal Register Volume 70, Number 140 (Friday, July 22, 2005)]
[Notices]
[Pages 42351-42352]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-14498]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to the indicated 
licensing contact at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
Maryland 20852-3804; telephone: (301) 496-7057; fax: (301) 402-0220. A 
signed Confidential Disclosure Agreement will be required to receive 
copies of the patent applications.

Adult Human Dental Pulp Stem Cells in vitro and in vivo

Dr. Songtao Shi et al. (NIDCR)
U.S. Patent Application No. 10/333,522 filed 17 Jan 2003 (HHS Reference 
No. E-233-2000/0-US-03), claiming priority to 21 Jul 2000.
Licensing Contact: Marlene Shinn-Astor; (301) 435-4426; 
shinnm@mail.nih.gov

    .Many individuals with ongoing and severe dental problems are faced 
with the prospect of permanent tooth loss. Examples include dentinal 
degradation due to caries or periodontal disease; (accidental) injury 
to the mouth; and surgical removal of teeth due to tumors associated 
with the jaw. Clearly, a technology that offers a possible alternative 
to artificial dentures by designing and transplanting a set of living 
teeth fashioned from the patient's own pulp cells would greatly improve 
the individual's quality of life.
    The NIH announces a new technology wherein dental pulp stem cells 
from an individual's own postnatal dental pulp tissue (one or two 
wisdom teeth) can potentially be used to engineer healthy living teeth. 
This technology is based upon the discovery of a subpopulation of cells 
within normal human dental

[[Page 42352]]

pulp tissue that has the ability to grow and proliferate in vitro. 
These (dental pulp) stem cells can be induced under defined culture 
conditions to form calcified nodules in vitro and have been shown to 
differentiate into a dentin/pulp like structure in vivo.

Postnatal Stem Cells and Uses Thereof

Drs. Songtao Shi and Pamela Robey (NIDCR)
PCT Application No. PCT/US03/12276 filed 19 Apr 2003 (HHS Reference No. 
E-018-2003/0-PCT-01), which published as WO 2004/094588 A2 on 04 Nov 
2004.
Licensing Contact: Marlene Shinn-Astor; (301) 435-4426; 
shinnm@mail.nih.gov.

    Many individuals with ongoing and severe dental problems are faced 
with the prospect of permanent tooth loss. Examples of such dental 
problems include: Dentinal degradation due to chronic dental disease 
(caries or periodontal); mouth injury; or through surgical removal, 
such as with tumors associated with the jaw. For many, a technology 
that offers a possible alternative to artificial dentures by designing 
and transplanting a set of living teeth fashioned from an individual's 
own pulp cells would greatly improve their quality of life.
    The NIH announces a new technology wherein human postnatal 
deciduous dental pulp stem cells commonly known as ``baby teeth'', are 
used to create dentin and have been shown to differentiate into cells 
of specialized function such as neural cells, adipocytes, and 
odontoblasts. It is believed that these cells could be manipulated to 
repair damaged teeth, induce the regeneration of bone, and treat neural 
injury or disease.
    This research is described, in part, in Miura et al., ``SHED: Stem 
cells from human exfoliated deciduous teeth,'' Proc. Natl. Acad. Sci. 
USA, vol. 100 (no. 10; May 13, 2003) pp. 5807-5812.

Multipotent Postnatal Stem Cells From Human Periodontal Ligament and 
Uses Thereof

Dr. Songtao Shi et al. (NIDCR)
PCT Application No. PCT/US04/39248 filed 22 Nov 2004 (HHS Reference No. 
E-033-2004/0-PCT-02), claiming priority to 20 Nov 2003.
    Licensing Contact: Marlene Shinn-Astor; (301) 435-4426; 
shinnm@mail.nih.gov.

    It is estimated that over 40 percent of the adult population in the 
United States has periodontal disease in one form or another. 
Periodontal Disease is a chronic infection of the periodontal ligament 
(PDL) and the adjacent bone and cementum. The effects of Periodontal 
Disease range from simple gum inflammation to, in extreme cases, tooth 
loss.
    The NIH announces a new technology wherein stem cells from the PDL 
have been isolated from adult human PDL. These cells are capable of 
forming cementum and PDL in immunocompromised mice. In cell culture, 
PDL stem cells differentiate into collagen fiber forming cells 
(fibroblasts), cementoblasts, and adipocytes. It is anticipated that 
these PDL stem cells will be useful for periodontal tissue regeneration 
to treat periodontal disease.

    Dated: July 15, 2005.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 05-14498 Filed 7-21-05; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.